AJMC® in the Press, October 28, 2022

Outpatient treatment with axi-cel shows promising response rates for relapsed large B-cell lymphoma, enhancing accessibility in community oncology settings.

A new FDA-approved blood test for Alzheimer disease could transform diagnosis and treatment accessibility, according to this conversation with Howard Fillit, MD, and Anthony “Nino” Sireci, MD, MSc.

Underdosing, poor spleen response, and transfusion dependence drive inferior survival outcomes in intermediate-1 myelofibrosis.

In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.

Cardiologists, nephrologists, and payers met in Scottsdale, Arizona, on August 26, 2025, to share insights on how team members can work together, empowered by data, to achieve value-based management of cardio-renal-metabolic syndrome.

Zanubrutinib shows superior progression-free and overall survival in relapsed mantle cell lymphoma compared with acalabrutinib, according to a new analysis.